SG11201407752YA - Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof - Google Patents
Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereofInfo
- Publication number
- SG11201407752YA SG11201407752YA SG11201407752YA SG11201407752YA SG11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA
- Authority
- SG
- Singapore
- Prior art keywords
- shanghai
- lllll
- pyrrolo
- triazine compound
- llll
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
(i2) m (19) mmRrm$k H » M (io) (43)SI^^0 _ 2013^-12^5 0 (05.12.2013) W i P O I P T C WO 2013/177983 A1 (51) C07D 487/04 (2006.01) C07D 519/00 (2006.01) A61K 31/5377 (2006.01) A61K31/5386 (2006.01) A61P 35/00 (2006.01) PCT/CN2013/074559 2013^4^23 0 (23.04.2013) (21) (22) (25) lift: (26) (30) 201210177980.3 2012^5^310 (31.05.2012) CN (71) (SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES) [CN/CN]; ^ S±J§7frM 555 Shanghai 201203 (CN) = (72) £®JA:##6& (YANG, Chunhao); 'I'N kity ilwilj 555 Shanghai 201203 (CN) = M (MENG, Linghua); ^ 2. 555 ^ , Shanghai 201203 (CN) = |5£ ft Q (CHEN, Yanhong); ^ S±>$TtM^K 555 Shanghai 201203 (CN) o jE# (WANG, Xi- ang); ^ 555 Shang hai 201203 (CN) = (TAN, Cun); ^ S ± M ft M 555 Shanghai 201203 (CN) = ^ mm (LI, Jiapeng); 4^ S_h$|ri] 555 Shanghai 201203 (CN) o T # (DING, Jian); 4^ S -t 'M flT M IJEL 74 1 jf& 555 -5§\", Shanghai 201203 (CN)= (CHEN,Yi); 555 Shanghai 201203 (CN) = (74) ftiSA: (KINGSOUND & PARTNERS); 116 B ® 11 M, Beijing 100097 (CN) = (8i) P): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZWo (84) I)''): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), 3E (AM, AZ, (54) Title: PYRROLO[2,l-F][l,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THERE OF = (54) : Pttn#[2, l-f][l, 2, 4]#: m oo o\ i> i> i-H cn i-H o CJ o & (I) (57) Abstract: The present invention relates to a pyrrolo[2,l-f][l,2,4]triazine compound, an isomer thereof or a pharmaceutical^ ac - ceptable salt, ester or hydrate thereof, and preparation a method and application thereof. The pyrrolo[2,l-f][l,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,l-f][l,2,4]triazine compound expressed in general formula (I) can in hibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinosit ol-3 kinase related diseases such as cancer. j, ni® l-f][l, 2, 4]# t), i-f][i, 2, 4]#^i|g|i^tJj Wjfi5£ ; (I) (I) ifeKlftlWp, l-f][l, 2, 3-#SS (PI3K) WO 2013/177983 A11 lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll lllll lllll llll lllllll llll llll llll BY, KG, KZ, RU, TJ, TM), 14 ;fll (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, - 21 &(3»=
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210177980.3A CN103450204B (en) | 2012-05-31 | 2012-05-31 | Pyrroles [2,1-f] [1,2,4] triazin compound, Preparation Method And The Use |
PCT/CN2013/074559 WO2013177983A1 (en) | 2012-05-31 | 2013-04-23 | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407752YA true SG11201407752YA (en) | 2015-01-29 |
Family
ID=49672377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407752YA SG11201407752YA (en) | 2012-05-31 | 2013-04-23 | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US9447101B2 (en) |
EP (1) | EP2857403B1 (en) |
JP (1) | JP6067107B2 (en) |
KR (1) | KR101824299B1 (en) |
CN (1) | CN103450204B (en) |
AU (1) | AU2013270326B2 (en) |
BR (1) | BR112014029708B1 (en) |
CA (1) | CA2874062C (en) |
ES (1) | ES2703934T3 (en) |
HK (1) | HK1203499A1 (en) |
MX (1) | MX359207B (en) |
RU (1) | RU2589053C1 (en) |
SG (1) | SG11201407752YA (en) |
WO (1) | WO2013177983A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
EP2948454B1 (en) | 2013-01-24 | 2017-05-31 | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) | Triazine compounds and a process for preparation thereof |
US10214537B2 (en) | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017040448A1 (en) * | 2015-08-31 | 2017-03-09 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
CN109641909B (en) | 2016-06-25 | 2022-01-11 | 苏州开拓药业股份有限公司 | Mechanism targets for rapamycin signaling pathway inhibitors and therapeutic applications thereof |
CN109111447A (en) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7- substituted azole triazin compounds or its pharmaceutically available salt, and its preparation method and application |
EP3670513B1 (en) * | 2017-08-15 | 2023-09-20 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Fgfr inhibitor and medical application thereof |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CA3154079A1 (en) | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
CN112851563A (en) * | 2020-12-30 | 2021-05-28 | 安徽金鼎医药股份有限公司 | Synthesis process of N-amino-3-azabicyclo [3,3,0] octane hydrochloride |
TW202313056A (en) * | 2021-09-10 | 2023-04-01 | 大陸商上海海和藥物研究開發股份有限公司 | PHARMACEUTICAL COMBINATIONS COMPRISING A PI3K <i>α</i> INHIBITOR |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
TW200635927A (en) | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
US7619083B2 (en) | 2005-07-01 | 2009-11-17 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
KR101443400B1 (en) | 2006-07-07 | 2014-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | Pyrrolotriazine kinase inhibitors |
EP2050749B1 (en) * | 2006-08-08 | 2017-11-22 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivative as pi3k inhibitor and use thereof |
JP5284977B2 (en) * | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
US8148522B2 (en) | 2007-01-02 | 2012-04-03 | Bristol-Myers Squibb Company | Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate |
WO2008131050A1 (en) | 2007-04-18 | 2008-10-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
KR20100083170A (en) * | 2007-10-16 | 2010-07-21 | 와이어쓰 엘엘씨 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
CL2009000241A1 (en) * | 2008-02-07 | 2010-09-03 | Chugai Pharmaceutical Co Ltd | Compounds derived from 5- (2-morpholin-4-yl-7h-pyrrolo [2,3-d] pyrimidin-4-yl) pyrimidin-2-ylamine; Preparation process; pharmaceutical composition; and use of the compounds to treat or prevent a proliferative disease such as cancer. |
US20110269740A1 (en) | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
WO2010002954A1 (en) * | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
WO2010092340A1 (en) * | 2009-02-13 | 2010-08-19 | Ucb Pharma S.A. | Fused pyridine and pyrazine derivatives as kinase inhibitors |
AU2010238361B2 (en) * | 2009-04-16 | 2015-08-06 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Imidazopyrazines for use as kinase inhibitors |
CA2787714C (en) * | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
WO2011141713A1 (en) * | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
CN102675323B (en) * | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | Pyrrole-[2, 1-f] [1, 2 and 4] triazine derivative and antitumor effect thereof |
-
2012
- 2012-05-31 CN CN201210177980.3A patent/CN103450204B/en active Active
-
2013
- 2013-04-23 RU RU2014147863/04A patent/RU2589053C1/en active
- 2013-04-23 WO PCT/CN2013/074559 patent/WO2013177983A1/en active Application Filing
- 2013-04-23 US US14/403,014 patent/US9447101B2/en active Active
- 2013-04-23 ES ES13798006T patent/ES2703934T3/en active Active
- 2013-04-23 SG SG11201407752YA patent/SG11201407752YA/en unknown
- 2013-04-23 JP JP2015514329A patent/JP6067107B2/en active Active
- 2013-04-23 EP EP13798006.6A patent/EP2857403B1/en active Active
- 2013-04-23 CA CA2874062A patent/CA2874062C/en active Active
- 2013-04-23 AU AU2013270326A patent/AU2013270326B2/en active Active
- 2013-04-23 KR KR1020147033824A patent/KR101824299B1/en active IP Right Grant
- 2013-04-23 MX MX2014014622A patent/MX359207B/en active IP Right Grant
- 2013-04-23 BR BR112014029708-8A patent/BR112014029708B1/en active IP Right Grant
-
2015
- 2015-04-27 HK HK15104065.5A patent/HK1203499A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN103450204B (en) | 2016-08-17 |
US9447101B2 (en) | 2016-09-20 |
KR20150009565A (en) | 2015-01-26 |
JP2015518010A (en) | 2015-06-25 |
US20150141644A1 (en) | 2015-05-21 |
AU2013270326B2 (en) | 2016-07-14 |
MX2014014622A (en) | 2015-08-10 |
ES2703934T3 (en) | 2019-03-13 |
AU2013270326A1 (en) | 2014-12-18 |
BR112014029708B1 (en) | 2023-05-02 |
EP2857403B1 (en) | 2018-10-10 |
EP2857403A4 (en) | 2015-10-21 |
CN103450204A (en) | 2013-12-18 |
WO2013177983A1 (en) | 2013-12-05 |
HK1203499A1 (en) | 2015-10-30 |
RU2589053C1 (en) | 2016-07-10 |
BR112014029708A8 (en) | 2021-09-08 |
KR101824299B1 (en) | 2018-03-14 |
MX359207B (en) | 2018-09-19 |
CA2874062A1 (en) | 2013-12-05 |
EP2857403A1 (en) | 2015-04-08 |
BR112014029708A2 (en) | 2017-06-27 |
JP6067107B2 (en) | 2017-01-25 |
CA2874062C (en) | 2015-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407752YA (en) | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof | |
SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201406775UA (en) | Injectable formulation | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators |